Head and Neck Cancer SPORE at the University of Wisconsin

项目摘要 威斯康星州头颈部孢子旨在促进转化实验室和临床研究， 改善头颈癌（HNC）患者的总体预后。这种高度合作的研究 基础科学家与HNC临床医生合作，为这一复杂的癌症人群推进新的治疗策略。 这些患者由于肿瘤的关键解剖位置而承受不成比例的负担。 一种疾病，治疗可以损害语言，吞咽和呼吸功能，除了创造 身体外观和社会交往能力的显著改变。努力提高治愈率 必须仔细平衡，努力减少治疗毒性，以提高患者的整体生活质量。 患者该SPORE的主要目标是：1）促进HNC的多学科转化研究， 2)改善HNC患者的总生存期和生活质量，3）纳入新的预测模型进行测试 新的HNC治疗策略，4）提高对免疫调节如何增强 HNC中的常规和实验性治疗反应，5）翻译开发的有前景的新分子 在威斯康星州大学和工业通过临床前测试和进入HNC临床试验。的 威斯康星州HN SPORE设计了三个主要研究项目。项目1将联合收割机 放射性核素治疗（TRT）与免疫检查点抑制（ICI），以刺激增强的HNC反应 在I期临床试验中达到顶峰。项目2建立了一个强大的患者特异性生物工程HNC 从患者细胞中提取模型系统，该模型系统结合了肿瘤微环境的成分， 预测HNC患者的治疗反应。使用模型中的治疗反应数据的可行性， 将在临床初步研究中测试有根据术后放射治疗。项目3审查了双重目标， 介导免疫微环境变化的关键受体酪氨酸激酶Axl和MerTK， 从而增强HNC患者的肿瘤反应。威斯康星州孢子将支持这项研究， 核心（行政，病理学和生物统计学），职业提升计划和发展 研究计划。

PROJECT SUMMARY The Wisconsin Head and Neck SPORE is designed to promote translational laboratory and clinical research to improve overall outcome for patients with Head and Neck Cancer (HNC). This highly collaborative research links basic scientists with HNC clinicians to advance novel treatment strategies for this complex cancer population. These patients bear a disproportionate burden from their cancers based on the critical anatomic location of the disease for which treatment can compromise speech, swallow, and breathing function, in addition to creating significant alterations in physical appearance and capacity for social interaction. Efforts to improve cure rates must be carefully balanced with efforts to reduce treatment toxicity to enable enhanced overall quality of life for patients. The broad objectives of this SPORE are to: 1) Promote multidisciplinary translational research in HNC, 2) Improve overall survival and quality of life for patients with HNC, 3) Incorporate new predictive models to test novel HNC treatment strategies, 4) Improve understanding of how immune modulation can augment conventional and experimental treatment responses in HNC, 5) Translate promising new molecules developed at the University of Wisconsin and from Industry through preclinical testing and into HNC clinical trials. The Wisconsin HN SPORE has designed three primary research projects. Project 1 will combine targeted radionuclide therapies (TRT) with immune checkpoint inhibition (ICI) to stimulate enhanced HNC response profiles culminating in a Phase I clinical trial. Project 2 builds a powerful patient-specific bioengineered HNC model system from patient cells that incorporates components of the tumor microenvironment to more accurately predict HNC patient treatment response. The feasibility of using treatment response data from the model to inform postoperative radiation therapy will be tested in a clinical pilot study. Project 3 examines dual targeting of critical receptor tyrosine kinases Axl and MerTK to mediate changes in the immune microenvironment and thereby augment tumor response in HNC patients. The Wisconsin SPORE will support this research with three Cores (Administrative, Pathology and Biostatistics), a Career Enhancement Program and a Developmental Research Program.